NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.
NeoPhore's investors include Neva SGR, Bristol-Myers Squibb, Innovate UK, LIFTT, Claris Ventures.
NeoPhore is headquartered in Cambridge, United Kingdom.
NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.
NeoPhore is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NeoPhore — Funding & Investors." VCBacked, May 22, 2024, https://www.vcbacked.co/company/neophore. Accessed August 13, 2026.
VCBacked. (2024). NeoPhore — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/neophore
{{cite web |title=NeoPhore — Funding & Investors |url=https://www.vcbacked.co/company/neophore |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated